{"filings":[{"id":170541,"accession_number":"0001193125-25-057850","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Bala S. Manian resigns from Vaccinex board effective March 18, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bala S. Manian resigned as a director of Vaccinex, Inc. effective immediately on March 18, 2025.","Departure was not due to any disagreement with the Company on operations, policies, or practices.","No replacement or further board changes announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170540,"accession_number":"0001193125-25-049988","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2025-03-07T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Vaccinex voluntarily delists from Nasdaq; Form 25 filing expected March 17, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq trading suspended since December 18, 2024 following a hearing panel determination to delist.","Company notified Nasdaq on March 7, 2025 of its intention to delist; filing Form 25 on or about March 17.","Stock will continue to trade on OTC Pink under symbol VCNX.","Vaccinex plans to continue development of pepinemab in Alzheimer's and cancer via partnerships and grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187535,"accession_number":"0001193125-24-280155","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Vaccinex receives Nasdaq delisting notice; trading suspended Dec 18, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel determined to delist VCNX for failing to maintain $2.5M minimum stockholders' equity.","Trading suspension effective at open of trading on Wednesday, December 18, 2024.","Company expects common stock to be quoted on OTC Markets Group under symbol VCNX.","Press release issued December 17, 2024 announcing the delisting determination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187534,"accession_number":"0001193125-24-258757","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises $2.15M in private placement of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 76,909 shares at $3.25/share and pre-funded warrants for 584,646 shares at $3.2499 each.","Private placement closed Nov 14, 2024; aggregate gross proceeds of approx. $2.15 million.","Investors include FCMI Parent Co. (controlled by Chair Albert Friedberg) and Vaccinex (Rochester) L.L.C. (controlled by CEO Maurice Zauderer).","Pre-funded warrants exercisable immediately at $0.0001/share with a 39.99% beneficial ownership limitation.","Agreement includes participation rights in any subsequent offering and customary resale registration rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187533,"accession_number":"0001193125-24-235251","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaccinex receives Nasdaq delisting notice for failing equity standard; will appeal","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement for continued listing.","Nasdaq granted extension until Sept 30, 2024, to regain compliance; company did not comply.","On Oct 7, 2024, Nasdaq determined to delist unless company timely appeals to a Hearings Panel.","Company intends to appeal, which automatically stays suspension and delisting pending Panel decision.","No assurance that Hearings Panel will grant continued listing or that compliance will be achieved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204021,"accession_number":"0001193125-24-221790","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$6.2M via warrant exercise & new warrant issuance; insiders participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders exercised 1,067,492 existing warrants at $5.636/share; gross proceeds ~$6.2M.","Company issued 1,601,238 new warrants at $0.125 each, exercisable at $5.636, expiring 2029.","Insiders (chair and CEO controlled entities) participated; shares/warrants issued in private placement.","Company must file resale registration statement by Oct 17, 2024 for new warrant underlying shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204020,"accession_number":"0001193125-24-218870","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex director Chrystyna Bedrij Stecyk resigns effective September 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chrystyna Bedrij Stecyk resigned as director of Vaccinex, Inc. effective immediately.","Resignation was not due to any disagreement with the Company on operations, policies, or practices.","No replacement director was announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204019,"accession_number":"0001193125-24-203149","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vaccinex calls warrants after positive Alzheimer's trial FDG-PET signal","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Warrants from Oct/Nov 2023, Feb/Mar 2024 financings called for cancellation at $0.0001/share.","Call triggered by statistically significant increase in FDG-PET signal in SIGNAL-AD pepinemab trial.","Warrant holders have 20 or 30 trading days to exercise; unexercised warrants auto-cancel.","Company plans to explore additional financing options, including warrant inducement or exchange.","No guarantee of warrant exercise or success of any potential financing transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204018,"accession_number":"0001193125-24-200272","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex reports pepinemab slows cognitive decline in MCI due to AD; plans partnership","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pepinemab showed significant reduction in brain metabolic decline (FDG-PET) in medial temporal cortex (p=0.0297) vs placebo.","In MCI patients, reduced astrocyte reactivity (GFAP) and neuronal damage marker p-tau217; no effect in early dementia.","Cognitive decline slowed in MCI per iADRS and ADAS-Cog13; no benefit in early dementia group.","Company plans to pursue a development partnership to reduce operating expenses going forward.","Pepinemab was well-tolerated, consistent with prior Huntington's disease studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204017,"accession_number":"0001193125-24-189569","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.","Secondary endpoint: statistically significant increase in FDG-PET signal in medial temporal cortex (p=0.0297) in MCI patients over 12 months.","Results echo prior Phase 2 Huntington's data, suggesting similar mechanism targeting astrocyte activation.","Company actively pursuing a pharmaceutical partner for late-stage development in Alzheimer's disease.","Pepinemab has been well-tolerated in over 600 patients across AD, HD, and MS trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220716,"accession_number":"0001193125-24-155612","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.","Database lock expected in June; key outcomes including safety, FDG-PET, and plasma GFAP biomarkers to be reported in July.","Pepinemab targets SEMA4D to inhibit astrocyte reactivity and neuroinflammation, a differentiated mechanism vs. anti-amyloid antibodies.","Study funded by $4.75M from ADDF and $0.75M grant from Alzheimer's Association."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220715,"accession_number":"0001193125-24-135285","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex shareholders elect directors, approve say-on-pay and incentive plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Jacob Frieberg, Albert Friedberg, and Maurice Zauderer as directors with >425k votes each.","Advisory say-on-pay passed with 521,607 votes for vs 27,555 against.","Shareholders chose annual frequency for future say-on-pay votes (539,907 for 1 year).","First amendment to 2018 Omnibus Incentive Plan approved 403,835 for, 146,143 against.","Ratified Deloitte & Touche as auditor for FY2024 with 674,404 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220714,"accession_number":"0001193125-24-094701","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaccinex receives Nasdaq notice for failing minimum equity requirement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on April 11, 2024: Vaccinex lacks $2.5M minimum stockholders' equity for continued listing.","Company also fails alternative standards: market value of listed securities $35M or net income $500k.","Deadline to submit compliance plan is May 13, 2024; Nasdaq may grant extension if plan accepted.","No immediate delisting, but failure to regain compliance could lead to delisting of VCNX common stock.","Management evaluating options but cannot assure regaining or maintaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220713,"accession_number":"0001193125-24-083568","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$4.5M via multiple equity financings; issues Series A Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds: ~$1.5M from RDO + PIPE (193K shares and warrants at $7.77/unit).","Additional Private Placement: ~$1.25M from 159,683 shares and warrants at $7.77/unit; insiders participated.","ADDF Transaction: $1.75M from Series A Preferred (5% cumulative dividend, convertible) and warrants for 229,057 shares.","Warrants exercisable at $7.64/share, 5-year term; callable after positive SIGNAL-AD Alzheimer's data release.","Lock-up on insiders through May 12, 2024; company restricted from most equity issuances until June 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240336,"accession_number":"0001193125-24-080804","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex closes $1.5M registered direct offering of 193K shares and warrants at $7.77 combined","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed registered direct offering of 193,000 shares and warrants for 193,000 shares at $7.77 per unit.","Gross proceeds of approximately $1.5 million from the offering.","Offering previously disclosed on March 27, 2024; closings occurred March 28, 2024.","Concurrent private placement of Common Warrants to purchase up to 193,000 shares of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240335,"accession_number":"0001193125-24-078295","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Vaccinex raises ~$1.5M via public offering of 193K shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering combines 193,000 common shares with warrants to purchase equivalent shares at $7.77 per unit.","Gross proceeds of approximately $1.5 million; closing expected on March 28, 2024.","Company prohibited from issuing or announcing new equity for 90 days post-close, with exceptions for insider/charity offerings up to $3M total.","Prior at-the-market offering under Sale Agreement terminated effective March 26, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240334,"accession_number":"0001193125-24-057888","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex CFO Scott Royer to retire March 14; Controller Jill Sanchez named Interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Scott Royer notified retirement effective March 14, 2024, not due to any disagreement with the company.","Jill Sanchez, age 52, CPA, to serve as Interim CFO, Principal Financial and Accounting Officer from March 14.","Sanchez has been Vaccinex's Controller since January 2019; no family relationships or reportable transactions.","Royer will cease serving as Principal Financial and Principal Accounting Officer upon retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240333,"accession_number":"0001193125-24-040885","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex enters 8 ActivMAb agreements including 3 major pharma companies for complex membrane targets","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eight new antibody discovery agreements integrate ActivMAb platform, with 3 major pharma/biotech companies and 5 strategic antibody-service partners.","ActivMAb 'Antigen Virus' application targets difficult multi-pass membrane proteins such as GPCRs, ion channels, and chemokine receptors.","Technology enables antibody drug conjugate (ADC) development for cancer; platform uses purified viral presentation for efficient selection.","Agreements signed within last 3 months; CEO cites renewed market optimism after two-year biotech downturn as driver of interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240332,"accession_number":"0001193125-24-037078","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Vaccinex implements 1-for-14 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Split effective 5:00 p.m. ET Feb 19, 2024; shares trade split-adjusted from Feb 20.","Ratio 1-for-14, approved by board and stockholders; new CUSIP 918640301.","Complying with $1.00 minimum bid price required by Nasdaq by March 4, 2024.","Fractional shares rounded up; authorized shares unchanged; equity awards adjusted.","Shares continue trading under symbol VCNX; transfer agent is Computershare."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240331,"accession_number":"0001193125-24-033801","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex shareholders approve reverse stock split at ratio of 1:4 to 1:14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved by 7,075,432 votes for, 258,830 against, 37,142 abstain.","Board authorized to implement reverse split at any ratio between 1-for-4 and 1-for-14.","Action likely intended to regain compliance with Nasdaq minimum bid price requirement.","Exact ratio and timing to be determined by Board at its discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240329,"accession_number":"0001193125-24-027618","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K/A","filed_at":"2024-02-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Vaccinex amends 8-K to correct Form of Common Warrant filed with Feb. 6 offering","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amended Form 8-K filed solely to replace incorrect version of Exhibit 4.2 (Form of Common Warrant).","Corrected warrant form supersedes the one filed in error with the Original 8-K dated Feb. 7, 2024.","No other changes made to the Original 8-K; securities purchase agreement and other exhibits unchanged.","Original 8-K reported a securities purchase agreement and related warrants dated Feb. 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240330,"accession_number":"0001193125-24-026615","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$3.7M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issues 3.84M shares and warrants for 3.84M shares at $0.725 per unit; also 1.27M pre-funded warrants at $0.7249.","Common warrants exercisable at $1.00/share; pre-funded warrants at $0.0001; both immediately exercisable.","Investors include company chair Albert Friedberg (FCMI) and CEO Maurice Zauderer (Vaccinex Rochester).","Gross proceeds ~$3.7M; closing on Feb 8, 2024.","Executive officers and directors subject to 45-day lock-up on sales of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257829,"accession_number":"0001193125-23-263647","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex reports pepinemab significantly reduces GFAP biomarker in Huntington's disease; presented at CTAD.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pepinemab reduced plasma GFAP levels in HD patients vs placebo using highly sensitive S-PLEX immunoassay.","Data from podium presentation at CTAD Conference in Boston on October 26, 2023.","Prior phase 2 HD trial showed pepinemab prevented decline in glucose uptake and slowed cognitive decline (HD-CAB).","Ongoing SIGNAL-AD trial in Alzheimer's; last patient to complete 12-month treatment expected by June 2024.","Company sees pepinemab as potential alternative or complement to anti-Aβ antibodies for Alzheimer's."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257828,"accession_number":"0001193125-23-256153","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-10-13T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Vaccinex faces Nasdaq delisting over bid price; appeals, reports equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delisting determination on Oct 10, 2023 for failing minimum bid price compliance (bid below $1 for 30 days).","Company intends to appeal; appeal stays suspension pending Hearings Panel decision, so stock remains listed for now.","Believes regained compliance with Nasdaq equity standard (min $2.5M equity) after recent capital raises totaling ~$10.96M gross proceeds.","Recent raises: public offering of 9.6M shares for ~$9.6M (Oct 3), plus two private placements ($582k and $650k) and ATM sales (~$123k).","Caution that future compliance with bid price or equity standards is uncertain; no assurance of continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257827,"accession_number":"0001193125-23-250405","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Vaccinex raises ~$8.7M in public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 9.6M share equivalents (7.6M shares + 2M pre-funded warrants) at $1.00 per unit, raising ~$8.7M net.","Related parties (Chairman Friedberg and CEO Zauderer) purchased $3.5M of shares and warrants in the offering.","Common warrants have $1.00 exercise price, 5-year term; pre-funded warrants have $0.0001 exercise price.","Net proceeds to fund pepinemab development for Alzheimer's disease and cancer, plus working capital.","Insiders entered lock-up agreements through December 2, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275187,"accession_number":"0001193125-23-243082","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-09-27T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Vaccinex to present ActivMAb platform and pepinemab PDAC study at two conferences","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Presentation at CHI's DOT Conference on Sept 28: new ActivMAb application for multi-pass membrane proteins including CXCR5.","Poster on Phase 1b/2a pepinemab + avelumab in chemotherapy-refractory metastatic PDAC at AACR Pancreatic Cancer conference on Sept 29.","Dr. Ernest Smith to present at DOT; Dr. Luis Ruffolo of University of Rochester presents the PDAC poster.","Poster will be available on Vaccinex website under 'Investors/Presentations' starting Sept 27 at 5:30 pm ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275186,"accession_number":"0001193125-23-241942","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex presents pepinemab data at conferences; AD study completion expected Jun 2024, cancer ORR doubled","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pepinemab presentations at Keystone Symposia (Oct 1-5) and CTAD (Oct 24-27) featuring AD and cancer data.","SIGNAL-AD phase 1/2a fully enrolled; last patient completes treatment by June 2024; key endpoints FDG-PET, CDR-SB, ADAS-Cog13.","KEYNOTE-B84: In PD-L1 low HNSCC (CPS<20), ORR 21.1% and median PFS 5.79 months, ~2x historical checkpoint monotherapy.","Combination with KEYTRUDA induces organized lymphoid structures correlated with disease control and PFS (p=0.0056).","Vaccinex and Merck in preliminary stages of potential extension study adding chemotherapy to pepinemab+KEYTRUDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275185,"accession_number":"0001193125-23-240553","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Vaccinex implements 1-for-15 reverse stock split effective Sept 25, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-15 ratio, effective 5:00 p.m. ET on September 25, 2023.","Objective to regain compliance with Nasdaq $1.00 minimum bid price by October 9, 2023.","Stock to trade on Nasdaq under symbol VCNX on split-adjusted basis from September 26, 2023.","Fractional shares resulting from the split will be rounded up to the nearest whole share.","No change to authorized shares or par value; CUSIP changes to 918640202."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275184,"accession_number":"0001193125-23-240513","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$582,500 via private placement of 3.7M shares at $0.156/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 3,733,973 common shares at $0.156/sh to accredited investors for gross proceeds of ~$582,500.","CEO-controlled entity Vaccinex (Rochester), L.L.C. participated in the placement.","Company granted registration rights for resale of shares within 180 days of closing.","Proceeds to fund pepinemab development and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275183,"accession_number":"0001193125-23-233884","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex shareholders approve 1:15 reverse stock split; board sets ratio, effective Sept 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split amendment with 43,464,926 votes for, 2,041,760 against, 135,207 abstained.","Board set reverse split ratio at 1:15; effective date expected in September 2023, subject to final determination.","Prior to effective time, company will disclose final timing and additional details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275182,"accession_number":"0001193125-23-218037","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-08-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$650K in private placement of 3.14M shares at $0.207/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 3,140,095 shares to accredited investors at $0.207 per share for gross proceeds of approximately $650,000.","Shares sold in unregistered transaction under Section 4(a)(2) and Rule 506 of Regulation D.","Company to use net proceeds for pepinemab development, working capital, and general corporate purposes.","Registration rights agreement requires company to file resale registration statement within 120 days of closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292611,"accession_number":"0001193125-23-156073","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaccinex receives Nasdaq delisting notice for failing to meet $2.5M equity minimum","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity $2.4M as of March 31, 2023; below Nasdaq's $2.5M minimum.","Company has 45 days (until July 9, 2023) to submit a compliance plan to regain compliance.","If plan accepted, extension to Nov 21, 2023 possible; otherwise delisting may occur.","Company plans to submit plan and pursue capital raising, including recent private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292610,"accession_number":"0001193125-23-149499","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex files prospectus supplement for up to $4.39M ATM offering via Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May offer and sell up to $4,391,000 of common stock from time to time.","Sales agent Jefferies LLC under existing Open Market Sale Agreement dated March 27, 2020.","Proceeds used for general corporate purposes and clinical development.","Hogan Lovells opinion on validity of shares attached as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292609,"accession_number":"0001193125-23-145153","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$2.96M via private placement of 7.9M shares at $0.37428","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 7,908,516 shares at $0.37428/share for $2.96M gross proceeds; closed May 15, 2023.","Proceeds to fund pepinemab development in cancer/neurodegenerative disease and working capital.","FCMI Parent Co., controlled by chairman Albert D. Friedberg, participated in the offering.","Shares unregistered; exempt under Rule 506 and Section 4(a)(2); registration rights granted to other investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292608,"accession_number":"0001193125-23-142882","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex shareholders elect directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Gerald E. Van Strydonck and Barbara Yanni as directors for three-year terms ending 2026.","Van Strydonck received 26,745,493 votes for and 213,769 withheld; Yanni 26,763,394 for and 195,868 withheld.","Ratified Deloitte & Touche LLP as independent auditor for FY2023 with 34,406,314 for, 108,269 against, 83,727 abstentions.","Broker non-votes on director election were 7,639,048 for each nominee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292607,"accession_number":"0001193125-23-089004","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises ~$2.04M in private placement at $0.41/share; insider participation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4,975,608 shares at $0.41/share for gross proceeds of ~$2.04 million to three investors, including affiliates of CEO and chairman.","Proceeds will fund development and clinical trials of lead drug candidate pepinemab in cancer and neurodegenerative disease, plus working capital.","FCMI Parent Co., controlled by chairman Albert D. Friedberg, committed to purchase up to an additional $2.96 million of shares on or before May 15, 2023.","Albert Friedberg covenanted to vote his shares in excess of 40% proportionately with other holders; registration rights granted to non-affiliated investor.","Shares issued in private placement exempt from registration under Section 4(a)(2) of Securities Act and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313268,"accession_number":"0001193125-23-077886","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex awards stock options and raises base salaries for top executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Maurice Zauderer receives option for 56,000 shares at 110% of FMV, vesting over 4 years, 5-year expiry.","CSO Ernest Smith receives option for 40,000 shares; CFO Scott Royer receives option for 32,000 shares; vesting 4 years, 10-year expiry.","Base salaries increased 5% effective April 1: CEO $426,930, CSO $302,380, CFO $275,334."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313267,"accession_number":"0001193125-23-065339","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex enrolls 36 patients in KEYNOTE-B84 HNSCC study; interim analysis due mid-2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2 trial evaluating pepinemab + KEYTRUDA in recurrent/metastatic HNSCC.","Enrollment of 36 subjects triggers pre-planned interim analysis; results expected mid-2023.","Primary endpoints: safety (TEAEs) and objective response rate (ORR).","Company notes improved durable responses in PD-L1 low (CPS<20) patient subset.","Full study plans to enroll ~62 patients; pepinemab global rights held by Vaccinex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331797,"accession_number":"0001193125-22-292625","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-11-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Vaccinex raises $3.8M via private placement of 7.14M shares at $0.5293 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 7,142,496 shares to accredited investors for gross proceeds of ~$3.8 million.","Insider participation: CEO Maurice Zauderer, chairman Albert Friedberg, directors Jacob Frieberg and Gerald Van Strydonck.","Proceeds to fund pepinemab clinical trials and for working capital.","Registration rights agreement filed to register shares for resale within 75 days after closing.","Shares sold under Section 4(a)(2) and Rule 506 of Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331796,"accession_number":"0001193125-22-282054","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex reports 100% recurrence-free at 24 months in Stage III melanoma triple combination","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Triple combo (pepinemab+nivolumab+ipilimumab) achieved 100% recurrence-free survival at 24 months vs <40% for dual combos.","LAG-3 upregulation identified as resistance mechanism to pepinemab+nivolumab; rationale for triple with LAG-3 inhibitor.","Pepinemab combinations induced tertiary lymphoid structures and CD26hi CD4+ T cells in tumors.","Phase 1/2 trial enrolling for pepinemab+trastuzumab+DC vaccine in HER2+ metastatic breast cancer (NCT05378464).","Interim analysis of KEYNOTE-B84 (pepinemab+KEYTRUDA in HNSCC) expected in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331795,"accession_number":"0001193125-22-260706","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-10-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Vaccinex receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq letter on Oct 10, 2022: common stock bid price below $1.00 for 30 consecutive days through Oct 7.","Company has 180 days (until April 10, 2023) to regain compliance by closing at $1.00+ for 10 business days.","If not cured, may seek second 180-day period if meeting other listing standards; otherwise delisting risk.","Company to monitor bid price and evaluate options including reverse stock split to cure.","No immediate effect on listing; appeal rights exist if delisting notice issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349275,"accession_number":"0001193125-22-243745","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex presents neoadjuvant pepinemab combo data at ESMO; triple therapy shows 62.5% pCR in Stage III melanoma","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Triple combination (nivolumab/ipilimumab/pepinemab) achieved 62.5% pathologic complete response (pCR) and 75% major pathologic response.","Doublet pepinemab/nivolumab showed 25% pCR; pepinemab/ipilimumab 12.5% pCR; nivolumab alone 28.5% pCR.","Triple combination demonstrated significantly improved recurrence-free survival vs doublets (logrank p=0.0097).","All patients underwent surgery without delay; Grade 3 AEs were manageable (5/8 in triple arm).","Correlative biomarker data to be presented at 2022 SITC; further studies needed to confirm durability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349274,"accession_number":"0001193125-22-214504","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex announces publication of Phase 2 SIGNAL HD study in Nature Medicine showing pepinemab slows cognitive decline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 SIGNAL HD study results published in Nature Medicine (Aug 8, 2022) and Journal of Neuroinflammation.","Pepinemab significantly improved cognition in early manifest HD patients (HD-CAB Index p=0.007).","Pepinemab reduced caudate atrophy (p=0.017) and brain metabolic decline in FDG-PET.","Treatment was well-tolerated with 5% treatment-emergent adverse events vs 9% placebo.","Phase 1b/2a study of pepinemab in Alzheimer's disease initiated (NCT04381468)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349273,"accession_number":"0001193125-22-207791","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex presents pepinemab AD/HD data at AAIC 2022; SIGNAL-AD first patient completed with no safety concerns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Presented poster at AAIC 2022 on pepinemab (SEMA4D antibody) for Alzheimer's and Huntington's disease.","Phase 2 HD study showed pepinemab restored learning and increased brain metabolic activity (FDG-PET).","Ongoing Phase 1/2a SIGNAL-AD study: first patient completed with no safety concerns as of Q2 2022.","Pepinemab targets glial activation to reduce neuroinflammation; funded by Alzheimer's Association and ADDF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366170,"accession_number":"0001193125-22-171530","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Vaccinex presents at Jefferies conference on KEYNOTE-B84 study; no new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presented at Jefferies Healthcare Conference on June 10, 2022 at 10:30 a.m. ET.","Presentation covered the KEYNOTE-B84 study of pepinemab (anti-SEMA4D) in HNSCC.","Filing does not include any new clinical data or financial results.","Corporate slide deck furnished as Exhibit 99.1, available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366169,"accession_number":"0001193125-22-150166","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaccinex annual meeting: directors elected, Deloitte & Touche ratified as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chrystyna Bedrij Stecyk elected director with 20,338,061 votes for, 527,786 withheld.","Bala S. Manian elected director with 20,286,510 votes for, 579,337 withheld.","Deloitte & Touche ratified as auditor for FY2022 with 26,332,224 for, 185,405 against, 167,773 abstain.","Both director nominees elected for three-year terms expiring in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366168,"accession_number":"0001193125-22-095136","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-04-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex grants stock options and 7% salary increases to top executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Maurice Zauderer receives options for 28,000 shares at $1.29, vesting over 4 years.","CSO Ernest Smith gets options for 20,000 shares; CFO Scott Royer gets 16,000 shares at same price.","Base salaries raised 7%: Zauderer to $406,600, Smith to $287,981, Royer to $262,223.","Options granted under 2018 Omnibus Incentive Plan, expire 10 years from grant date April 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385654,"accession_number":"0001193125-22-069387","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaccinex director Jeff Goater will not stand for re-election at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeff Goater informed the company on March 3, 2022, that he will not seek re-election.","Departure is due to new responsibilities and conflicting demands on his time.","Mr. Goater confirmed no disagreement with company operations, policies, or practices.","His departure takes effect at the 2022 annual meeting of stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385653,"accession_number":"0001193125-22-023545","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-01-31T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Vaccinex raises $9.7M in private placement of 8.75M shares at $1.11; January equity total $13.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement closed Jan 31 with 8,747,744 shares at $1.11/share; gross proceeds ~$9.7M after amendment adding 2.8M shares.","Affiliated investors include CEO Maurice Zauderer ($2M), Chairman Albert Friedberg ($2M), and director Jacob Frieberg.","Additional $3.5M raised via ATM sales earlier in January at weighted avg $1.16/share, bringing month total to ~$13.2M.","Proceeds will fund development of lead drug candidate pepinemab in cancer and neurodegenerative disease.","Registration rights agreement requires filing resale shelf within 75 days; failure triggers liquidated damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385652,"accession_number":"0001193125-22-017722","cik":1205922,"company_name":"VACCINEX, INC.","ticker":"VCNX","form_type":"8-K","filed_at":"2022-01-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaccinex reports 2 complete responses in first 3 patients in Phase 1b KEYNOTE-B84 study for HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Two of three patients in Phase 1b safety segment achieved complete responses per RECIST v1.1.","Both responders had low PD-L1 expression (CPS<20); HPV-negative status.","Third patient had clinical progression and withdrew before week 9; SAEs attributed to pre-existing condition.","Expansion phase now open; will enroll up to 62 additional patients across 18 US sites.","Data safety monitoring board confirmed pepinemab (20 mg/kg Q3W) + KEYTRUDA (200 mg Q3W) well-tolerated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2940000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-01-26T23:59:59+00:00|385652"}